[Cortisone-induced osteoporosis: from physiopathogenesis to treatment].
Glucocorticoids are useful as therapeutic agents in a wide variety of clinical disorders for their antiinflammatory, immunosuppressive and cytolytic properties. When administered in supraphysiological doses they cause an array of undesired side-effects that greatly limit their clinical utility. Among them, the development of osteoporosis is critical. It is a multifactorial process with important actions occurring in bone and other sites. As a consequence, an uncoupling of bone turnover is observed with a decrease in bone formation and an increase in bone resorption. The efficacy of preventive and therapeutic interventions are limited but an area of new perspectives are currently under investigation.
Peretz
A
A
Service de Rhumatologie et de Médecine Physique, Hôpital Universitaire Saint-Pierre, Bruxelles.
D001862:Bone Resorption; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D003131:Combined Modality Therapy; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010012:Osteogenesis; D010024:Osteoporosis / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control
D005938:Glucocorticoids; D002118:Calcium
L'ostéoporose cortisonique: de la physiopathogénie au traitement.